Christopher Degnan - Galera Therapeutics Chief Officer
| GRTXDelisted Stock | USD 2.58 0.19 6.86% |
Insider
Christopher Degnan is Chief Officer of Galera Therapeutics
| Age | 44 |
| Phone | 610 725 1500 |
| Web | https://www.galeratx.com |
Galera Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5929) % which means that it has lost $0.5929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.6311) %, meaning that it created substantial loss on money invested by shareholders. Galera Therapeutics' management efficiency ratios could be used to measure how well Galera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Galera Therapeutics currently holds 152.3 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Galera Therapeutics has a current ratio of 4.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Galera Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Christine CPA | Mereo BioPharma Group | 43 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Prof MD | Hookipa Pharma | 80 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 61 | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Matthew CPA | PDS Biotechnology Corp | 55 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| John Lewicki | Mereo BioPharma Group | 72 | |
Management Performance
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 |
Galera Therapeutics Leadership Team
Elected by the shareholders, the Galera Therapeutics' board of directors comprises two types of representatives: Galera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galera. The board's role is to monitor Galera Therapeutics' management team and ensure that shareholders' interests are well served. Galera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mel MD, President CEO | ||
| Dr MBA, CoFounder COO | ||
| Jennifer Esq, Chief Secretary | ||
| Andie Collier, Chief Officer | ||
| FACS FACS, Chief Officer | ||
| Christopher Degnan, Chief Officer | ||
| PharmD MBA, Chief Officer | ||
| Jon MD, Ex Officer | ||
| Dennis Riley, Emeritus Officer | ||
| Judy Schnyder, Senior Management |
Galera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galera Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 146.68 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 36.15 % | ||||
| Shares Owned By Institutions | 18.95 % | ||||
| Number Of Shares Shorted | 2.12 M | ||||
| Price To Earning | (0.78) X | ||||
| Price To Book | 29.39 X | ||||
| EBITDA | (46.69 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Galera Stock
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |